

# PFIZER'S CTI REQUESTS PROPOSALS FOR BIOTHERAPEUTIC TARGETS

Pre-Proposal Deadline: April 24, 2017



**Pfizer's Centers for Therapeutic Innovation, or CTI**, is a unique program that collaborates with leading academic medical centers, the NIH, and foundations to speed the translation of novel targets to the clinic.

## Advantages to Collaborating with CTI

A partnership with CTI may include collaborative use of Pfizer's technologies, publishing rights, and financial awards in the form of milestone and royalty payments for successful programs, in addition to providing appropriate funds for carrying out the collaborative work.

Foundations collaborating with CTI include:

- Lupus Research Alliance
- Alzheimer's Drug Discovery Foundation
- Crohn's and Colitis Foundation of America
- Foundation for Sarcoidosis Research
- Juvenile Diabetes Research Foundation
- Jeffrey Modell Foundation

## Pre-proposal Submission Process

Submission entails a brief, non-confidential 2-3 page overview of the target, mechanism (including evidence for disease linkage), and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

## For Information

Please contact Mary Faris at [Mary.Faris@pfizer.com](mailto:Mary.Faris@pfizer.com) and Seema Basu at [ssbasu@partners.org](mailto:ssbasu@partners.org)

All researchers and clinicians whose work meets these criteria are invited to apply. **Please submit non-confidential pre-proposals to your Technology Transfer Office by April 24, 2017.**

## What We Look For

- **Strong project rationale**, demonstrated association between target biology and disease mechanism
- **Novel drug targets** with potential to lead to differentiated drugs
- **Link between target pathway and human disease**
- **Ability to address unmet medical needs**
- **Feasibility**: tractable target, discovery/ development plan

## Modalities

- **Large Molecules** (antibodies, proteins, peptides, ADCs, Fusions)

## Therapeutic Areas of Interest for Spring 2017

- **Oncology**: Immuno-oncology, targets that promote immune response, targets involved in oncogenic signaling and tumorigenesis, novel tumor-specific cell surface antigens or tumor targeting approach, tumor metabolism and epigenetics
- **Inflammation and immune disorders**: Rheumatoid Arthritis, lupus, Crohn's Disease and colitis, NASH, atopic dermatitis, cytokines and their signaling pathways, regulatory cells and tolerance induction, microbiome with an interest in epithelial barrier
- **Cardiovascular and metabolic diseases**: Cardiovascular disease and heart failure, NAFLD/NASH, and obesity/eating disorders
- **Neuroscience**: Alzheimer's Disease, Parkinson's Disease, chronic neuroinflammation mechanisms and mitochondrial biology impacting the pathologies of AD and PD, cerebral amyloid angiopathy and vascular impairment associated with neurodegeneration
- **Rare monogenic genetic diseases**: Hematologic (non-malignant), neuromuscular and pulmonary diseases, including PAH and cystic fibrosis



COLLABORATIVE

ENTREPRENEURIAL

RESULTS-DRIVEN